There were errors in two sentences within the section 'Epigenetic changes in SCLC', indicating that EZH2 suppresses ASCL1 expression by suppression of TGFβ signalling. Instead, EZH2 promotes ASCL1 expression by suppression of TGFβ signalling. This has been corrected in the online and print versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nrc.2017.87
Rights and permissions
About this article
Cite this article
Gazdar, A., Bunn, P. & Minna, J. Erratum: Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 17, 765 (2017). https://doi.org/10.1038/nrc.2017.106
Published:
Issue date:
DOI: https://doi.org/10.1038/nrc.2017.106
This article is cited by
-
Transcriptional regulatory network analysis identifies GRN as a key regulator bridging chemotherapy and immunotherapy response in small cell lung cancer
Journal of Hematology & Oncology (2025)
-
The current and emerging immunotherapy paradigm in small-cell lung cancer
Nature Cancer (2025)
-
Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer
Cell & Bioscience (2024)
-
Efficacy and toxicity of lurbinectedin in subsequent systemic therapy of extensive-stage small cell lung cancer: a meta-analysis
BMC Cancer (2024)
-
A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer
Scientific Reports (2024)
